De-Risking Immunotherapy Development: 5 Key Early Decisions, Upcoming Webinar Hosted by Xtalks
Source: PR NewswireView original on PR Newswire

In this free webinar, learn how early cross-functional decisions can help reduce risk across immunotherapy development. The featured speakers will discuss nonclinical strategy, potency, comparability, manufacturing changes and opportunities for early regulatory alignment. Attendees will also explore how addressing these issues earlier can reduce rework, avoid delays and strengthen development planning from preclinical stages through clinical translation.
TORONTO, Nov. 17, 2026 /PRNewswire/ -- Next-generation immunotherapies create interconnected CMC, nonclinical, clinical and regulatory challenges. If key decisions around potency, comparability, model relevance, biomarkers and first-in-human strategy are addressed too late, they can result in avoidable development delays and rework. Addressing these considerations early can help identify cross-functional risks, strengthen development strategies and support more informed decision-making throughout the development process.
This webinar brings together regulatory, CMC and nonclinical experts to explore five critical decisions that can strengthen an immunotherapy program from preclinical development through clinical translation and global development. The discussion will examine approaches to establishing credible nonclinical strategies when conventional models have limited relevance, anticipating potency and comparability challenges associated with manufacturing changes and identifying opportunities for early regulatory alignment. Attendees will gain insights into how these considerations can support more effective development planning and reduce potential setbacks as programs advance toward clinical evaluation.
Register for this webinar to learn how early strategic decisions can help reduce risks, minimize delays and strengthen immunotherapy development programs.
Join experts from ICON plc, Tamie Malaska, Director of Regulatory Affairs; Gabriel Bohl, Director, Regulatory Affairs CMC; and Philip Coan, Director of Drug Development Services, for the live webinar on Monday, December 7, 2026, at 10am EST (4pm CET / EU-Central).
For more information, or to register for this event, visit De-Risking Immunotherapy Development: 5 Key Early Decisions.
ABOUT XTALKS
Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.
Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.
To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/
Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/de-risking-immunotherapy-development-5-key-early-decisions-upcoming-webinar-hosted-by-xtalks-302941536.html
Source: PR NewswireView original on PR Newswire
Content provided by PR Newswire. Redistribution, resale or sublicensing is not permitted.